After our first therapist training protocol (cleared by the FDA as a Phase 1 study of MDMAs psychological effects on healthy subjects) was initially deferred by the institutional review board (IRB), we resubmitted the protocol to the IRB and addressed the IRBs concerns. The resubmission includes a cover letter, a deferral response, an amended informed consent form, and an amended protocol. The submission was accompanied by letters of support from University of West Georgia Psychology Professor Daniel A. Helminiak, Ph.D., and Johns Hopkins researcher William Richards, Ph.D. and a joint letter from Johns Hopkins research team Mathew Johnson, Ph.D., William Richards, Ph.D., and Roland Griffiths, Ph.D.